MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor
1997

MDM2 and p53 Expression in Gliomas

Sample size: 61 publication Evidence: moderate

Author Information

Author(s): P Korkolopoulou, P Christodoulou, K Kouzelis, M Hadjiyannakis, A Priftis, G Stamoulis, A Seretis, E Thomas-Tsagli

Primary Institution: Asklepeion Hospital, Voula, Athens, Greece

Hypothesis

The study aims to investigate the clinical significance of p53 and MDM2 oncoprotein expression in gliomas, as related to established prognostic factors.

Conclusion

The study establishes that p53 LI and MDM2 LI, along with proliferation markers, are significant indicators of overall and disease-free survival in diffuse astrocytoma patients.

Supporting Evidence

  • MDM2 and p53 were co-expressed in 28% of cases.
  • Older age, high histological grade, high PCNA labelling index, and high AgNOR score were associated with reduced overall survival.
  • p53 LI and MDM2 LI were independent predictors of disease-free survival.

Takeaway

This study found that certain proteins in brain tumors can help doctors predict how long patients might live after treatment.

Methodology

The study involved a multivariate survival analysis of 61 patients with CNS gliomas, assessing the expression of p53 and MDM2 proteins along with proliferation markers.

Limitations

The study was limited to diffuse astrocytomas and did not include other types of gliomas.

Participant Demographics

30 men and 21 women with a mean age of 55.4 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication